← Back to Search

Monoclonal Antibodies

INBRX-106 + Pembrolizumab for Lung Cancer

Verified Trial
Phase 1 & 2
Recruiting
Research Sponsored by Inhibrx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has your disease progressed or came back despite treatment?
Do you have locally advanced or metastatic non-small cell lung cancer?
Must not have
Has your tumor tested positive for the EGFR mutations and/or the ALK gene? Check your biomarker test results.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-4 years
Awards & highlights

Study Summary

This trial is studying a new drug to see if it is safe and effective at treating locally advanced or metastatic non small cell lung cancer when given in combination with pembrolizumab (Keytruda).

Who is the study for?
This trial is for adults with advanced non-small cell lung cancer who have tried at least one standard of care treatment. They must not have certain gene mutations (EGFR, ALK) or prior exposure to OX40 agonists and should be free of serious heart conditions, active infections, and immune-related side effects from previous therapies.Check my eligibility
What is being tested?
The study tests INBRX-106 alone and combined with Pembrolizumab (keytruda) in different doses to find the safest and most effective amount for treating solid tumors. See study design
What are the potential side effects?
Possible side effects include typical immune therapy reactions like inflammation in various organs, skin rashes, fatigue, and potential worsening of existing heart conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My disease has worsened or returned after treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab
To assess the safety and tolerability of INBRX-106 in in combination with pembrolizumab
Secondary outcome measures
To assess the immunogenicity of INBRX-106 in combination with pembrolizumab
To assess the pharmacokinetics of INBRX-106 in combination with pembrolizumab

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort F3b: Priming dose followed by INBRX-106 and PembrolizumabExperimental Treatment0 Interventions
Priming dose of 0.3 mg/kg of INBRX-106 in the first cycle, followed by 0.1mg/kg of INBRX-106 + pembrolizumab 200mg every 3 weeks.
Group II: Cohort F3a: Alternating dosing of INBRX-106 and PembrolizumabExperimental Treatment1 Intervention
Alternating dosing of INBRX-106 0.3mg/kg + pembrolizumab 400mg every 6 weeks

Find a Location

Who is running the clinical trial?

Inhibrx, Inc.Lead Sponsor
7 Previous Clinical Trials
1,402 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,868 Previous Clinical Trials
5,051,517 Total Patients Enrolled
Vasily Andrianov, MDStudy DirectorInhibrx, Inc.
4 Previous Clinical Trials
772 Total Patients Enrolled

Media Library

INBRX-106 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04198766 — Phase 1 & 2
Non-Small Cell Lung Cancer Research Study Groups: Cohort F3b: Priming dose followed by INBRX-106 and Pembrolizumab, Cohort F3a: Alternating dosing of INBRX-106 and Pembrolizumab
Non-Small Cell Lung Cancer Clinical Trial 2023: INBRX-106 Highlights & Side Effects. Trial Name: NCT04198766 — Phase 1 & 2
INBRX-106 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04198766 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What site did they apply to?
Valkyrie Clinical Trials
City of Hope
Renovatio Clinical (Woodlands)
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

Why did patients apply to this trial?

My Doctor told me that my life span is short. I want a help myself live and over come this disease.
PatientReceived 1 prior treatment
I do not want chemotherapy. I believe it does more damage than good. I want to do trial because the chemotherapy is juste keeping my Cancer stable so there is no positive results.
PatientReceived no prior treatments

How responsive is this trial?

Typically responds via
Phone Call
Average response time
  • < 2 Days
Most responsive sites:
  1. City of Hope: < 24 hours
  2. Henry Ford Health System: < 24 hours
  3. Valkyrie Clinical Trials: < 24 hours
~100 spots leftby Feb 2026